Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Common Equity (2016 - 2025)

Cryo Cell International (CCEL) has disclosed Common Equity for 16 consecutive years, with -$18.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 40.78% to -$18.6 million in Q4 2025 year-over-year; TTM through Nov 2025 was -$18.6 million, a 40.78% decrease, with the full-year FY2025 number at -$18.6 million, down 40.78% from a year prior.
  • Common Equity was -$18.6 million for Q4 2025 at Cryo Cell International, down from -$14.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $4.8 million in Q3 2021 to a low of -$18.6 million in Q4 2025.
  • A 5-year average of -$5.2 million and a median of -$2.0 million in 2021 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: soared 350.8% in 2022, then tumbled 59040.98% in 2024.
  • Cryo Cell International's Common Equity stood at $4.2 million in 2021, then crashed by 136.43% to -$1.5 million in 2022, then plummeted by 623.69% to -$11.0 million in 2023, then decreased by 19.81% to -$13.2 million in 2024, then crashed by 40.78% to -$18.6 million in 2025.
  • Per Business Quant, the three most recent readings for CCEL's Common Equity are -$18.6 million (Q4 2025), -$14.8 million (Q3 2025), and -$15.6 million (Q2 2025).